Use access key #2 to skip to page content.
  • S&P 500: 1,070.52
  • Change: 1.30%
$9.59 0.25 (2.68%)
2/9/2010 4:00 PM

Seattle Genetics, Inc. (SGEN)

CAPS Rating:
***

A biotechnology company, which develops monoclonal antibody-based therapies for the treatment of cancer and autoimmune diseases.

Rating a stock in CAPS consists of three components:

Your call - Will this stock outperform or underperform the S&P 500? Successful picks are measured in terms of whether or not you were correct and by how many percentage points.

Your time frame - A guideline for other members to see whether your thinking is short or long-term. Time frame is also used to calculate the stock rating, but is not used in the scoring of your pick.

Your pitch - Here's your chance to offer more detailed thoughts, analysis, concerns, or the rationale behind your call. The pitch is optional and may be added later.

Each time you rate a stock, CAPS updates the community intelligence for the company, which may or may not change its CAPS rating. For more information, visit the Help tab at the top of the page.

You aren't currently rating SGEN

Add Stock to Watchlist

What the Community Thinks

Total Members

273 Outperforms
22 Underperforms
 

All-Stars

65 Outperforms
9 Underperforms
 

Wall Street

10 Outperforms
1 Underperforms
 

Members bullish on SGEN are also bullish on:

Members bearish on SGEN are also bearish on:

Ticker Tags

Growth (1902), Healthcare (711), Biotechnology (220), Defensive (1457), Small Cap (1645), Aggressive Growth (860), Rule Breakers Universe (125)
Suggest a tag

Seattle Genetics, Inc. At A Glance

Current Price: $9.59
Last Trade Time: 2/9/2010 4:00 PM
Open: $9.47
Previous Close: $9.34
Daily Range: $9.34 - $9.76
52-Week Range: $7.00 - $14.94
Volume: 516,995
Market Cap: $964.10M
P/E Ratio: 0.00
Compare Our Special Broker Offers!

Stock Trends

SGEN VS S&P 500 (SPY)

News & Discussion Boards

Top Bull Pitch

Recs

1

Seattle Genetics, Inc. (SGEN)

Avatar TMFBreakerBrian (99.33) Submitted: 3/31/08 1:36 PM

Biopharmaceuticals are being valued at a premium and Seattle Genetics has the goods. Is it the blood cancer biologics version of solid tumor small molecule Exelixis?

Replies: 0 | Reply | Permalink

Top Bear Pitch

Recs

1

Seattle Genetics, Inc. (SGEN)

Avatar georicheck (32.80) Submitted: 8/03/07 11:48 AM

Needs a product to succeed.

Replies: 0 | Reply | Permalink

CAPS Members

picks per page. CHANGE

Results 1 - 5 of 46 :   1 2 3 4 5 Next » Jump to page:

Recs

0

 (SGEN)

Avatar gangsterchen (< 20) Submitted: 2/01/10 10:06 PM : Outperform Start Price: $10.23 SGEN Score: -4.39

unique technology that been licensed to many big pharma.

Report this Post Replies: 0 | Reply | Permalink

Recs

0

 (SGEN)

Avatar zzlangerhans (99.64) Submitted: 1/05/10 2:45 PM : Underperform Start Price: $10.51 SGEN Score: 3.32

Seattle G is back up over 10 on the strength of new deals with Takeda and Glaxo. But a one billion dollar cap seems excessive for a developmental biotech without a track record of success in advanced trials. Lead candidate dacetuzumab appears to be headed for the dustbin of history after the MARINER lymphoma trial was terminated for futility and Roche/Genentech broke up the partnership. Phase II data for brentuximab and lintuzumab are expected this year and could be positive catalysts, but at this cap the risk/reward ratio is tilted negative.

Report this Post Replies: 0 | Reply | Permalink

Recs

0

 (SGEN)

Avatar dcsccr (< 20) Submitted: 7/10/09 11:53 AM : Outperform Start Price: $8.87 SGEN Score: -14.50

antibodies and their conjugates are the future of cancer therapeutics

Report this Post Replies: 0 | Reply | Permalink

Recs

0

 (SGEN)

Avatar gokylego (82.62) Submitted: 4/28/09 11:01 PM : Outperform Start Price: $8.98 SGEN Score: -18.45

Partnered well with funding and a intriguing pipeline.

Report this Post Replies: 0 | Reply | Permalink

Recs

0

 (SGEN)

Avatar SpaceMonkey01 (52.64) Submitted: 3/29/09 12:28 PM : Outperform Start Price: $9.61 SGEN Score: -36.08

Moving Average Convergence/Divergence (MACD) indicates a Bullish Trend.
Chart pattern indicates a Strong Upward Trend.
Relative Strength is Bullish.
Up/Down volume pattern indicates that the stock is under Accumulation.
The 50 day Moving Average is rising which is Bullish.
The 200 day Moving Average is rising which is Bullish.
Look for Support at 9.89
Watch for resistance at 10.84

Report this Post Replies: 0 | Reply | Permalink

Results 1 - 5 of 46 :   1 2 3 4 5 Next » Jump to page:

Wall Street

Results 1 - 11 of 11  

picks per page. CHANGE

Top
Pick
Member NameMember RatingStart
Date
CallTime FrameStart
Price
Stock
Gain
S&P
Gain
ScorePitch
TrackJimCramer < 20 11/04/09 Underperform 3W $8.95+7.15%+2.19%-4.96
TrackDeutscheSec 89.68 08/13/09 Outperform NS $11.25-14.76%+8.21%-22.96
TrackOppenheimer 81.36 10/27/08 Outperform NS $8.28+15.82%+27.18%-11.36
TrackRBCCapMkts 86.33 03/19/08 Outperform NS $8.63+11.12%-16.70%+27.82
TrackMichaelBrus 92.73 02/14/08 Outperform 1Y $9.35+2.57%-17.33%+19.90
TrackJPMorgan 84.76 01/28/08 Outperform NS $9.34+2.68%-16.15%+18.83
TrackFortisBank 83.59 09/21/07 Outperform NS $11.79-18.66%-26.44%+7.78
TrackWMBlair 69.55 08/21/07 Outperform NS $11.03-13.06%-21.98%+8.93
TrackBofASec 94.61 12/12/06 Outperform NS $6.17+55.43%-19.68%+75.11
TrackNeedham 67.64 10/25/06 Outperform NS $4.92+94.92%-17.41%+112.32
TrackNextGen 85.60 10/06/06 Outperform NS $4.95+93.74%-15.62%+109.36

Results 1 - 11 of 11  

Beat this Stock

Clicking "Beat this Stock!" will bring you to a company with a higher rating than the one you're currently viewing.

Even though CAPS shows only one- to five-star rankings, behind the scenes, all companies in CAPS have a distinct numerical ranking. In other words, there is a No. 1 stock in CAPS and a worst-ranked stock in CAPS. When you arrive at the top-ranked stock, clicking "Beat this Stock!" will cause the page to refresh.

That is, until there is a new No. 1 stock!

These companies do not represent formal Motley Fool recommendations. Please do your own due diligence before investing. Fool on.

Featured Broker Partners

EQWEBD03 187ms